Zinger Key Points
- Hims & Hers Health reports quarterly GAAP earnings of 11 cents per share, which met the analyst consensus estimate.
- Quarterly revenue comes in at $481.14 million, which beat the analyst consensus estimate of $470.31 million.
- Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights.
Hims & Hers Health Inc. HIMS reported its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter.
The Details: Hims & Hers Health reported quarterly GAAP earnings of 11 cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $481.14 million, which beat the analyst consensus estimate of $470.31 million and is an increase over revenue of $246.62 million from the same period last year.
Hims & Hers subscribers grew to 2.2 million, up 45% year-over-year in 2024. Gross margin was 77% for the fourth quarter of 2024 compared to 83% for the fourth quarter of 2023.
Read Next: Palantir Extends Losses, Microsoft Slides: What’s Driving Markets Monday?
“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, Hims & Hers Health CEO.
“Over 2 million subscribers now entrust Hims & Hers to aid them in their journey to better health — with thousands more joining daily,” Dudum added.
Outlook: For the first quarter of 2025, Hims and Hers expects revenue of $520 million to $540 million and adjusted EBITDA of $55 million to $65 million, reflecting an adjusted EBITDA margin of 11% to 12%.
For the full year 2025, the company expects revenue of $2.3 billion to $2.4 billion and adjusted EBITDA of $270 million to $320 million, reflecting an adjusted EBITDA margin of 12% to 13%.
HIMS Price Action: According to data from Benzinga Pro, Hims & Hers Health shares are down 17.66% after hours at $42.25 Monday.
Image: Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.